Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial

Contraception

Volumn 77, Issue 4, 2008, Pages 249-256

  Koltun, William ^a   Lucky, Anne W ^b   Thiboutot, Diane ^c   Niknian, Minoo ^d   Sampson Landers, Carole ^d   Korner, Paul ^e   Marr, Joachim ^f  

^a Medical Center for Clinical Research   (United States)

^b Dermatology Research Associates   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Clinical Development   (United States)

^e Women's Healthcare   (United States)

^f BAYER PHARMA AG   (Germany)

Author keywords

Acne vulgaris; Combined oral contraceptives; Drospirenone; Ethinyl estradiol

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PLACEBO;

ABDOMINAL PAIN; ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENORRHAGIA; MENTAL INSTABILITY; METRORRHAGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; STATISTICAL ANALYSIS; TOOTH DISEASE; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 40649128938     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.11.003     Document Type: Article

References (21)

1. Shaw J.C. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 3 (2002) 571-578
2. Thiboutot D.M. Acne. An overview of clinical research findings. Dermatol Clin 15 (1997) 97-109
3. Thiboutot D., and Chen W. Update and future of hormonal therapy in acne. Dermatology 206 (2003) 57-67
4. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 63 (2003) 1579-1596
5. Murphy A., Cropp C.S., Smith B.S., Burkman R.T., and Zacur H.A. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril 53 (1990) 35-39
6. van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., and Thijssen J.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 41 (1990) 345-352
7. Thorneycroft I.H., Gollnick H., and Schellschmidt I. Superiority of a combined oral contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 74 (2004) 123-130
8. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
9. Muhn P., Fuhrmann U., Fritzemeier K.H., Krattenmacher R., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 761 (1995) 311-335
10. van Vloten W.A., van Haselen C.W., van Zuuren E.J., et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69 Suppl 4 (2002) 2-15
11. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., and Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
12. Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 mcg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
13. Klipping C., Marr J., and Korner P. Ovulation inhibition effects of two low-dose OC dosing regimens following intentional dosing errors. Obstet Gynecol 107 (2006) 49S
14. Yonkers K.A., Brown C., Pearlstein T.B., et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
15. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
16. Redmond G.P., Olson W.H., Lippman J.S., Kafrissen M.E., Jones T.M., and Jorizzo J.L. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89 (1997) 615-622
17. Lucky A.W., Henderson T.A., Olson W.H., Robisch D.M., Lebwohl M., and Swinyer L.J. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37 (1997) 746-754
18. Thiboutot D., Archer D.F., Lemay A., Washenik K., Roberts J., and Harrison D.D. A randomized, controlled trial of a low-dose contraceptive containing 20 mcg of ethinyl estradiol and 200 mcg of levonorgestrel for acne treatment. Fertil Steril 76 (2001) 461-468
19. Leyden J., Shalita A., Hordinsky M., Swinyer L., Stanczyk F.Z., and Weber M.E. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol 47 (2002) 399-409
20. Maloney J.M., Kunz M., Lee-Rugh S., et al. Drospirenone 3 mg/ethinylestradiol 20 mcg COC in the Treatment of acne vulgaris: lesion count, ISGA. Abstract presented at ACOG: 5-9 May 2007, San Diego, CA, Convention Center (2007)
21. Maloney J.M., Kunz M., Lee-Rugh S., Sampson-Landers C., Niknian M., and Korner P. Drospirenone 3 mg/ethinylestradiol 20 mcg COC in the treatment of acne vulgaris: Investigator and subject self-assessment. Abstract presented at ACOG: 5-9 May 2007, San Diego, CA, Convention Center (2007)